Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402714 · ClinicalTrials.gov registry record · Phase 2
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
A Phase 2 study of Hematologic Malignancies, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 3
- Study locations
NCT00402714: Completed Phase 2 study of Hematologic Malignancies, sponsored by Yale University.
NCT00402714 is a Phase 2 study of Hematologic Malignancies that has completed, run by Yale University. The registered enrollment target is 14 participants, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00402714, a Phase 2 study of Hematologic Malignancies, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a study to explore the use of a reduced intensity transplant conditioning regimen. A conditioning regimen is the treatment that is given to prepare a body for the new bone marrow that will be received from a donor. Reduced intensity conditioning uses lower doses of chemotherapy than conventional conditioning regimens. The use of lower doses of drugs and radiation cause fewer side effects. Reduced intensity regimens have been offered to older patients or patients at increased risk for transplant-related side effects and have been shown to be safe and effective. Reduced intensity conditioning regimens are now considered for many patients who are undergoing transplant.
Conditions Studied
Interventions
- RADIATION Total Body Irradiation
- DRUG Pentostatin
- PROCEDURE extracorporeal photopheresis
Study Locations (3)
Connecticut
- Yale Comprehensive Cancer Center at Yale University School of Medicine - New Haven
Massachusetts
- Tufts-New England Medical Center - Boston
Texas
- Methodist Hospital - Texas Transplant Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00402714 record still lists
NCT00402714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Total Body Irradiation is the first listed.
NCT00402714 reports a single indexed study location in Connecticut, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT00402714 about?
NCT00402714 is a clinical study titled "A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies". This is a study to explore the use of a reduced intensity transplant conditioning regimen. A conditioning regimen is the treatment that is given to prepare a body for the new bone marrow that will be received from a donor. Reduced intensity conditioning uses lower doses of chemotherapy than conventi...
What is the current status of trial NCT00402714?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-07. Estimated completion is 2009-08.
What conditions does trial NCT00402714 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT00402714?
The interventions under investigation include: Total Body Irradiation (RADIATION), Pentostatin (DRUG), extracorporeal photopheresis (PROCEDURE).
Who is sponsoring clinical trial NCT00402714?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00402714 being conducted?
This trial has 3 study locations across Connecticut, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00402714's enrollment target sits among peer trials
14 43rd of 45 higher than 2 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 2
-
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RECRUITING · Phase 2
-
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
RECRUITING · Phase 2
-
IVIG for Infection Prevention After CAR-T-Cell Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia